Mobile phone use and risks of overall and 25 site-specific cancers: a prospective study from the UK Biobank Study
Menée à l'aide de données de la "UK Biobank" portant sur 431 861 personnes (âge : 38-73 ans ; 46 % d'hommes ; durée médiane de suivi : 10,7 ans), cette étude analyse l'association entre l'utilisation d'un téléphone mobile et le risque de cancer (25 localisations) en fonction du sexe
Background: The association between mobile phone use and incident cancers remains uncertain. We aimed to investigate the relationships of mobile phone use with incident overall and 25 site-specific cancers in men and women. Methods: 431,861 participants aged 38-73 years without prior cancers were included from the UK Biobank. Of these, 46.7% were male. Participants who used a mobile phone at least once per week to make or receive calls were defined as mobile phone users. The study outcomes were incident overall and 25 site-specific cancers. Results: During a median follow-up of 10.7 years, 35,401 (17.5%) men and 30,865 (13.4%) women developed overall cancer. Mobile phone use was significantly associated with higher risks of incident overall cancer (HR, 1.09; 95%CI: 1.06-1.12), nonmelanoma skin cancer (NMSC) (HR, 1.08; 95%CI: 1.03-1.14), urinary tract cancer (HR, 1.18; 95%CI:1.05-1.32) and prostate cancer (HR, 1.19; 95%CI: 1.13-1.25) in men, and incident overall cancer (HR, 1.03; 95%CI: 1.00-1.06), NMSC (HR, 1.07; 95%CI: 1.01-1.13), and vulva cancer (HR,1.74; 95%CI: 1.00-3.02) in women, but not with other cancers. Among mobile phone users, there was a dose-response relationship of length of mobile phone use with incident NMSC in men and women, and prostate cancer in men (all P for trend<0.05). Conclusions: There was a dose-response relationship of length of mobile phone use with incident NMSC in men and women, and prostate cancer in men. Impact: Our findings underscore the importance of limiting mobile phone use or keeping a distance from mobile phone for primary prevention of NMSC and prostate cancer.